Cargando…

Emerging Roles of Tumor Necrosis Factor-Stimulated Gene-6 in the Pathophysiology and Treatment of Atherosclerosis

Tumor necrosis factor-stimulated gene-6 (TSG-6) is a 35-kDa glycoprotein that has been shown to exert anti-inflammatory effects in experimental models of arthritis, acute myocardial infarction, and acute cerebral infarction. Several lines of evidence have shed light on the pathophysiological roles o...

Descripción completa

Detalles Bibliográficos
Autores principales: Watanabe, Rena, Sato, Yuki, Ozawa, Nana, Takahashi, Yui, Koba, Shinji, Watanabe, Takuya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5855687/
https://www.ncbi.nlm.nih.gov/pubmed/29401724
http://dx.doi.org/10.3390/ijms19020465
_version_ 1783307155131072512
author Watanabe, Rena
Sato, Yuki
Ozawa, Nana
Takahashi, Yui
Koba, Shinji
Watanabe, Takuya
author_facet Watanabe, Rena
Sato, Yuki
Ozawa, Nana
Takahashi, Yui
Koba, Shinji
Watanabe, Takuya
author_sort Watanabe, Rena
collection PubMed
description Tumor necrosis factor-stimulated gene-6 (TSG-6) is a 35-kDa glycoprotein that has been shown to exert anti-inflammatory effects in experimental models of arthritis, acute myocardial infarction, and acute cerebral infarction. Several lines of evidence have shed light on the pathophysiological roles of TSG-6 in atherosclerosis. TSG-6 suppresses inflammatory responses of endothelial cells, neutrophils, and macrophages as well as macrophage foam cell formation and vascular smooth muscle cell (VSMC) migration and proliferation. Exogenous TSG-6 infusion and endogenous TSG-6 attenuation with a neutralizing antibody for four weeks retards and accelerates, respectively, the development of aortic atherosclerotic lesions in ApoE-deficient mice. TSG-6 also decreases the macrophage/VSMC ratio (a marker of plaque instability) and promotes collagen fibers in atheromatous plaques. In patients with coronary artery disease (CAD), plasma TSG-6 levels are increased and TSG-6 is abundantly expressed in the fibrous cap within coronary atheromatous plaques, indicating that TSG-6 increases to counteract the progression of atherosclerosis and stabilize the plaque. These findings indicate that endogenous TSG-6 enhancement and exogenous TSG-6 replacement treatments are expected to emerge as new lines of therapy against atherosclerosis and related CAD. Therefore, this review provides support for the clinical utility of TSG-6 in the diagnosis and treatment of atherosclerotic cardiovascular diseases.
format Online
Article
Text
id pubmed-5855687
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-58556872018-03-20 Emerging Roles of Tumor Necrosis Factor-Stimulated Gene-6 in the Pathophysiology and Treatment of Atherosclerosis Watanabe, Rena Sato, Yuki Ozawa, Nana Takahashi, Yui Koba, Shinji Watanabe, Takuya Int J Mol Sci Review Tumor necrosis factor-stimulated gene-6 (TSG-6) is a 35-kDa glycoprotein that has been shown to exert anti-inflammatory effects in experimental models of arthritis, acute myocardial infarction, and acute cerebral infarction. Several lines of evidence have shed light on the pathophysiological roles of TSG-6 in atherosclerosis. TSG-6 suppresses inflammatory responses of endothelial cells, neutrophils, and macrophages as well as macrophage foam cell formation and vascular smooth muscle cell (VSMC) migration and proliferation. Exogenous TSG-6 infusion and endogenous TSG-6 attenuation with a neutralizing antibody for four weeks retards and accelerates, respectively, the development of aortic atherosclerotic lesions in ApoE-deficient mice. TSG-6 also decreases the macrophage/VSMC ratio (a marker of plaque instability) and promotes collagen fibers in atheromatous plaques. In patients with coronary artery disease (CAD), plasma TSG-6 levels are increased and TSG-6 is abundantly expressed in the fibrous cap within coronary atheromatous plaques, indicating that TSG-6 increases to counteract the progression of atherosclerosis and stabilize the plaque. These findings indicate that endogenous TSG-6 enhancement and exogenous TSG-6 replacement treatments are expected to emerge as new lines of therapy against atherosclerosis and related CAD. Therefore, this review provides support for the clinical utility of TSG-6 in the diagnosis and treatment of atherosclerotic cardiovascular diseases. MDPI 2018-02-05 /pmc/articles/PMC5855687/ /pubmed/29401724 http://dx.doi.org/10.3390/ijms19020465 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Watanabe, Rena
Sato, Yuki
Ozawa, Nana
Takahashi, Yui
Koba, Shinji
Watanabe, Takuya
Emerging Roles of Tumor Necrosis Factor-Stimulated Gene-6 in the Pathophysiology and Treatment of Atherosclerosis
title Emerging Roles of Tumor Necrosis Factor-Stimulated Gene-6 in the Pathophysiology and Treatment of Atherosclerosis
title_full Emerging Roles of Tumor Necrosis Factor-Stimulated Gene-6 in the Pathophysiology and Treatment of Atherosclerosis
title_fullStr Emerging Roles of Tumor Necrosis Factor-Stimulated Gene-6 in the Pathophysiology and Treatment of Atherosclerosis
title_full_unstemmed Emerging Roles of Tumor Necrosis Factor-Stimulated Gene-6 in the Pathophysiology and Treatment of Atherosclerosis
title_short Emerging Roles of Tumor Necrosis Factor-Stimulated Gene-6 in the Pathophysiology and Treatment of Atherosclerosis
title_sort emerging roles of tumor necrosis factor-stimulated gene-6 in the pathophysiology and treatment of atherosclerosis
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5855687/
https://www.ncbi.nlm.nih.gov/pubmed/29401724
http://dx.doi.org/10.3390/ijms19020465
work_keys_str_mv AT watanaberena emergingrolesoftumornecrosisfactorstimulatedgene6inthepathophysiologyandtreatmentofatherosclerosis
AT satoyuki emergingrolesoftumornecrosisfactorstimulatedgene6inthepathophysiologyandtreatmentofatherosclerosis
AT ozawanana emergingrolesoftumornecrosisfactorstimulatedgene6inthepathophysiologyandtreatmentofatherosclerosis
AT takahashiyui emergingrolesoftumornecrosisfactorstimulatedgene6inthepathophysiologyandtreatmentofatherosclerosis
AT kobashinji emergingrolesoftumornecrosisfactorstimulatedgene6inthepathophysiologyandtreatmentofatherosclerosis
AT watanabetakuya emergingrolesoftumornecrosisfactorstimulatedgene6inthepathophysiologyandtreatmentofatherosclerosis